XML 43 R32.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Development, Commercialization and Supply Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Product Approval | The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:
Country |  | MARINE |  | REDUCE-IT |  | Launch Date
Lebanon |  | March 2018 |  | August 2021 |  | June 2018
United Arab Emirates |  | July 2018 |  | October 2021 |  | February 2019
Qatar |  | December 2019 |  | April 2021 |  | N/A
Bahrain |  | April 2021 |  | April 2022 |  | N/A
Kuwait |  | December 2021 |  | March 2023 |  | September 2023
Saudi Arabia |  | March 2022 |  | June 2023 |  | September 2023
Changes in Balances of Contract Assets and Liabilities and Revenues Recognized | The following table presents changes in the balances of the Company’s contract assets and liabilities for years ended December 31, 2023 and 2022:
In thousands |  | Balance at Beginning of Period |  |  | Additions |  |  | Deductions |  |  | Balance at End of Period |
Year ended December 31, 2023: |  |  |  |  |  |  |  |  |  |  |  |
Contract assets |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Contract liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 15,346 |  |  | $ | 8,090 |  |  | $ | (18,586 | ) |  | $ | 4,850 |
Year ended December 31, 2022: |  |  |  |  |  |  |  |  |  |  |  |
Contract assets |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Contract liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 16,709 |  |  | $ | 6 |  |  | $ | (1,369 | ) |  | $ | 15,346 |
During the years ended December 31, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:
In thousands |  | Twelve Months Ended December 31, |
Revenue recognized in the period from: |  | 2023 |  |  | 2022 |
Amounts included in contract liability at the beginning of the period |  | $ | 1,892 |  |  | $ | 1,366 |
Performance obligations satisfied in previous periods |  | $ | 16,182 |  |  | $ | 2 |

X
- Definition Summary of product approval. + References No definition available. + Details
Name: | amrn_SummaryOfProductApprovalTableTextBlock
Namespace Prefix: | amrn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration